Is Tesla Stock Overvalued or a Buy for the Next Decade?
Shares of EV major Tesla (NASDAQ:TSLA) have experienced extreme volatility…
Sell
22
ADAP Quote, Financials, Valuation and Earnings
Last price:
$0.27
Seasonality move
:
-11%
Day range:
$0.28 - $0.30
52-week range:
$0.20 - $1.48
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.40x
P/B ratio:
6.03x
Volume:
540.1K
Avg. volume:
1.4M
1-year change:
-73.3%
Market cap:
$74.3M
Revenue:
$178M
EPS (TTM):
-$0.31
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ADAP
Adaptimmune Therapeutics PLC
|
$6.6M | -$0.17 | -91.39% | -8.33% | $1.58 |
|
AUTL
Autolus Therapeutics PLC
|
$2M | -$0.25 | -80.39% | -10.73% | $9.97 |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -- | -- | $17.94 |
|
MREO
Mereo BioPharma Group PLC
|
$15.9M | -$0.01 | -100% | -87.66% | $7.66 |
|
NCNA
NuCana PLC
|
-- | -$0.01 | -- | -99.69% | $104.00 |
|
VRNA
Verona Pharma PLC
|
$54.8M | -$0.03 | -- | -99.24% | $94.10 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ADAP
Adaptimmune Therapeutics PLC
|
$0.28 | $1.58 | $74.3M | -- | $0.00 | 0% | 0.40x |
|
AUTL
Autolus Therapeutics PLC
|
$1.57 | $9.97 | $417.8M | -- | $0.00 | 0% | -- |
|
BDRX
Biodexa Pharmaceuticals PLC
|
$1.15 | $17.94 | $2.9M | -- | $0.00 | 0% | 1.20x |
|
MREO
Mereo BioPharma Group PLC
|
$2.18 | $7.66 | $346.6M | -- | $0.00 | 0% | -- |
|
NCNA
NuCana PLC
|
$0.04 | $104.00 | $236.2K | -- | $0.00 | 0% | -- |
|
VRNA
Verona Pharma PLC
|
$75.61 | $94.10 | $6.4B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ADAP
Adaptimmune Therapeutics PLC
|
-211.44% | 3.631 | 50.03% | 1.57x |
|
AUTL
Autolus Therapeutics PLC
|
-- | 1.803 | -- | 8.74x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | 2.357 | -- | 1.20x |
|
MREO
Mereo BioPharma Group PLC
|
-- | 0.393 | -- | -- |
|
NCNA
NuCana PLC
|
-- | -0.390 | -- | -- |
|
VRNA
Verona Pharma PLC
|
51.62% | 0.242 | 4.47% | 8.30x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ADAP
Adaptimmune Therapeutics PLC
|
$6.4M | -$44.1M | -107.36% | -199.63% | -619.47% | -$67.8M |
|
AUTL
Autolus Therapeutics PLC
|
-$9M | -$65.2M | -49.92% | -49.92% | -643.43% | -$83.8M |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
MREO
Mereo BioPharma Group PLC
|
-- | -$11M | -- | -- | -- | -$8.6M |
|
NCNA
NuCana PLC
|
-- | -$1.6M | -- | -- | -- | -$9.3M |
|
VRNA
Verona Pharma PLC
|
$72.8M | -$10.3M | -51.07% | -85.84% | -8.34% | -$12.1M |
Adaptimmune Therapeutics PLC vs. Competitors
-
Which has Higher Returns ADAP or AUTL?
Autolus Therapeutics PLC has a net margin of -653.18% compared to Adaptimmune Therapeutics PLC's net margin of -781.13%. Adaptimmune Therapeutics PLC's return on equity of -199.63% beat Autolus Therapeutics PLC's return on equity of -49.92%.
Company Gross Margin Earnings Per Share Invested Capital ADAPAdaptimmune Therapeutics PLC87.93% -$0.18 -$12M AUTLAutolus Therapeutics PLC-99.86% -$0.26 $371.1M -
What do Analysts Say About ADAP or AUTL?
Adaptimmune Therapeutics PLC has a consensus price target of $1.58, signalling upside risk potential of 462.34%. On the other hand Autolus Therapeutics PLC has an analysts' consensus of $9.97 which suggests that it could grow by 534.82%. Given that Autolus Therapeutics PLC has higher upside potential than Adaptimmune Therapeutics PLC, analysts believe Autolus Therapeutics PLC is more attractive than Adaptimmune Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings ADAPAdaptimmune Therapeutics PLC3 3 0 AUTLAutolus Therapeutics PLC7 0 0 -
Is ADAP or AUTL More Risky?
Adaptimmune Therapeutics PLC has a beta of 2.857, which suggesting that the stock is 185.668% more volatile than S&P 500. In comparison Autolus Therapeutics PLC has a beta of 1.767, suggesting its more volatile than the S&P 500 by 76.723%.
-
Which is a Better Dividend Stock ADAP or AUTL?
Adaptimmune Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Autolus Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adaptimmune Therapeutics PLC pays -- of its earnings as a dividend. Autolus Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ADAP or AUTL?
Adaptimmune Therapeutics PLC quarterly revenues are $7.3M, which are smaller than Autolus Therapeutics PLC quarterly revenues of $9M. Adaptimmune Therapeutics PLC's net income of -$47.6M is higher than Autolus Therapeutics PLC's net income of -$70.2M. Notably, Adaptimmune Therapeutics PLC's price-to-earnings ratio is -- while Autolus Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adaptimmune Therapeutics PLC is 0.40x versus -- for Autolus Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ADAPAdaptimmune Therapeutics PLC0.40x -- $7.3M -$47.6M AUTLAutolus Therapeutics PLC-- -- $9M -$70.2M
-
Which has Higher Returns ADAP or BDRX?
Biodexa Pharmaceuticals PLC has a net margin of -653.18% compared to Adaptimmune Therapeutics PLC's net margin of --. Adaptimmune Therapeutics PLC's return on equity of -199.63% beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital ADAPAdaptimmune Therapeutics PLC87.93% -$0.18 -$12M BDRXBiodexa Pharmaceuticals PLC-- -- $6M -
What do Analysts Say About ADAP or BDRX?
Adaptimmune Therapeutics PLC has a consensus price target of $1.58, signalling upside risk potential of 462.34%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.94 which suggests that it could grow by 1460.34%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Adaptimmune Therapeutics PLC, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Adaptimmune Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings ADAPAdaptimmune Therapeutics PLC3 3 0 BDRXBiodexa Pharmaceuticals PLC1 0 0 -
Is ADAP or BDRX More Risky?
Adaptimmune Therapeutics PLC has a beta of 2.857, which suggesting that the stock is 185.668% more volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.154, suggesting its more volatile than the S&P 500 by 15.371%.
-
Which is a Better Dividend Stock ADAP or BDRX?
Adaptimmune Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adaptimmune Therapeutics PLC pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ADAP or BDRX?
Adaptimmune Therapeutics PLC quarterly revenues are $7.3M, which are larger than Biodexa Pharmaceuticals PLC quarterly revenues of --. Adaptimmune Therapeutics PLC's net income of -$47.6M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Adaptimmune Therapeutics PLC's price-to-earnings ratio is -- while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adaptimmune Therapeutics PLC is 0.40x versus 1.20x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ADAPAdaptimmune Therapeutics PLC0.40x -- $7.3M -$47.6M BDRXBiodexa Pharmaceuticals PLC1.20x -- -- --
-
Which has Higher Returns ADAP or MREO?
Mereo BioPharma Group PLC has a net margin of -653.18% compared to Adaptimmune Therapeutics PLC's net margin of --. Adaptimmune Therapeutics PLC's return on equity of -199.63% beat Mereo BioPharma Group PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ADAPAdaptimmune Therapeutics PLC87.93% -$0.18 -$12M MREOMereo BioPharma Group PLC-- -$0.10 -- -
What do Analysts Say About ADAP or MREO?
Adaptimmune Therapeutics PLC has a consensus price target of $1.58, signalling upside risk potential of 462.34%. On the other hand Mereo BioPharma Group PLC has an analysts' consensus of $7.66 which suggests that it could grow by 251.6%. Given that Adaptimmune Therapeutics PLC has higher upside potential than Mereo BioPharma Group PLC, analysts believe Adaptimmune Therapeutics PLC is more attractive than Mereo BioPharma Group PLC.
Company Buy Ratings Hold Ratings Sell Ratings ADAPAdaptimmune Therapeutics PLC3 3 0 MREOMereo BioPharma Group PLC6 0 0 -
Is ADAP or MREO More Risky?
Adaptimmune Therapeutics PLC has a beta of 2.857, which suggesting that the stock is 185.668% more volatile than S&P 500. In comparison Mereo BioPharma Group PLC has a beta of 0.465, suggesting its less volatile than the S&P 500 by 53.542%.
-
Which is a Better Dividend Stock ADAP or MREO?
Adaptimmune Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mereo BioPharma Group PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adaptimmune Therapeutics PLC pays -- of its earnings as a dividend. Mereo BioPharma Group PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ADAP or MREO?
Adaptimmune Therapeutics PLC quarterly revenues are $7.3M, which are larger than Mereo BioPharma Group PLC quarterly revenues of --. Adaptimmune Therapeutics PLC's net income of -$47.6M is lower than Mereo BioPharma Group PLC's net income of -$12.9M. Notably, Adaptimmune Therapeutics PLC's price-to-earnings ratio is -- while Mereo BioPharma Group PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adaptimmune Therapeutics PLC is 0.40x versus -- for Mereo BioPharma Group PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ADAPAdaptimmune Therapeutics PLC0.40x -- $7.3M -$47.6M MREOMereo BioPharma Group PLC-- -- -- -$12.9M
-
Which has Higher Returns ADAP or NCNA?
NuCana PLC has a net margin of -653.18% compared to Adaptimmune Therapeutics PLC's net margin of --. Adaptimmune Therapeutics PLC's return on equity of -199.63% beat NuCana PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ADAPAdaptimmune Therapeutics PLC87.93% -$0.18 -$12M NCNANuCana PLC-- -$0.32 -- -
What do Analysts Say About ADAP or NCNA?
Adaptimmune Therapeutics PLC has a consensus price target of $1.58, signalling upside risk potential of 462.34%. On the other hand NuCana PLC has an analysts' consensus of $104.00 which suggests that it could grow by 266566.67%. Given that NuCana PLC has higher upside potential than Adaptimmune Therapeutics PLC, analysts believe NuCana PLC is more attractive than Adaptimmune Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings ADAPAdaptimmune Therapeutics PLC3 3 0 NCNANuCana PLC0 1 0 -
Is ADAP or NCNA More Risky?
Adaptimmune Therapeutics PLC has a beta of 2.857, which suggesting that the stock is 185.668% more volatile than S&P 500. In comparison NuCana PLC has a beta of 1.639, suggesting its more volatile than the S&P 500 by 63.921%.
-
Which is a Better Dividend Stock ADAP or NCNA?
Adaptimmune Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adaptimmune Therapeutics PLC pays -- of its earnings as a dividend. NuCana PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ADAP or NCNA?
Adaptimmune Therapeutics PLC quarterly revenues are $7.3M, which are larger than NuCana PLC quarterly revenues of --. Adaptimmune Therapeutics PLC's net income of -$47.6M is lower than NuCana PLC's net income of -$836.1K. Notably, Adaptimmune Therapeutics PLC's price-to-earnings ratio is -- while NuCana PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adaptimmune Therapeutics PLC is 0.40x versus -- for NuCana PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ADAPAdaptimmune Therapeutics PLC0.40x -- $7.3M -$47.6M NCNANuCana PLC-- -- -- -$836.1K
-
Which has Higher Returns ADAP or VRNA?
Verona Pharma PLC has a net margin of -653.18% compared to Adaptimmune Therapeutics PLC's net margin of -21.4%. Adaptimmune Therapeutics PLC's return on equity of -199.63% beat Verona Pharma PLC's return on equity of -85.84%.
Company Gross Margin Earnings Per Share Invested Capital ADAPAdaptimmune Therapeutics PLC87.93% -$0.18 -$12M VRNAVerona Pharma PLC95.53% -$0.16 $468.3M -
What do Analysts Say About ADAP or VRNA?
Adaptimmune Therapeutics PLC has a consensus price target of $1.58, signalling upside risk potential of 462.34%. On the other hand Verona Pharma PLC has an analysts' consensus of $94.10 which suggests that it could grow by 24.45%. Given that Adaptimmune Therapeutics PLC has higher upside potential than Verona Pharma PLC, analysts believe Adaptimmune Therapeutics PLC is more attractive than Verona Pharma PLC.
Company Buy Ratings Hold Ratings Sell Ratings ADAPAdaptimmune Therapeutics PLC3 3 0 VRNAVerona Pharma PLC7 0 0 -
Is ADAP or VRNA More Risky?
Adaptimmune Therapeutics PLC has a beta of 2.857, which suggesting that the stock is 185.668% more volatile than S&P 500. In comparison Verona Pharma PLC has a beta of 0.206, suggesting its less volatile than the S&P 500 by 79.434%.
-
Which is a Better Dividend Stock ADAP or VRNA?
Adaptimmune Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verona Pharma PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adaptimmune Therapeutics PLC pays -- of its earnings as a dividend. Verona Pharma PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ADAP or VRNA?
Adaptimmune Therapeutics PLC quarterly revenues are $7.3M, which are smaller than Verona Pharma PLC quarterly revenues of $76.3M. Adaptimmune Therapeutics PLC's net income of -$47.6M is lower than Verona Pharma PLC's net income of -$16.3M. Notably, Adaptimmune Therapeutics PLC's price-to-earnings ratio is -- while Verona Pharma PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adaptimmune Therapeutics PLC is 0.40x versus -- for Verona Pharma PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ADAPAdaptimmune Therapeutics PLC0.40x -- $7.3M -$47.6M VRNAVerona Pharma PLC-- -- $76.3M -$16.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Apple Stock Undervalued or Overvalued?
For many years, Apple (NASDAQ:AAPL) was just about the perfect…
Where Will Palo Alto Networks Stock Be in 5 Years?
You know those companies that just refuse to slow down…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
68
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
58
TNXP alert for May 28
Tonix Pharmaceuticals Holding [TNXP] is up 1.57% over the past day.
Sell
37
ATS alert for May 28
ATS [ATS] is down 1.27% over the past day.
Buy
88
SMR alert for May 28
NuScale Power [SMR] is down 0.37% over the past day.
